Genetic Testing in Men With mCRPC
William Oh shared a post on LinkedIn about a recent paper by Pedro Barata et al. published in JAMA Oncology, commenting:
“How can we deliver precision medicine if we do not test for the presence of actionable mutations? In this RWD paper in JAMA Oncology by Pedro C Barata, MD MSc FACP and colleagues, <38% of CRPC patients had HRR (eg BRCA2) testing at all.
We know that up to 25% of these men may have germline or somatic mutations, and with multiple FDA-approved PARP inhibitors, many patients are not given a chance to receive life-prolonging therapy. Implementation of the care we already know works has to be a priority.”
“Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer”
Authors: Pedro C. Barata, Jonathan Assayag, Benjamin Li, Gordon Siu, Alexander Niyazov.
Source: William Oh/LinkedIn
William K. Oh is an American medical oncologist, academic, and industry leader, recognized for his expertise in managing genitourinary cancers, such as prostate, renal, bladder, and testicular cancers.
Oh serves as the Chief Medical Officer for the Prostate Cancer Foundation, the foremost philanthropic organization dedicated to prostate cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023